Genomes and Genes
Summary: Endogenous or exogenous chemicals that regulate the WATER-ELECTROLYTE BALANCE in the body. They consist of peptides and non-peptide compounds.
Publications178 found, 100 shown here
- Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptakeAndrew D Michaels
Division of Cardiology, Department of Medicine, University of California at San Francisco Medical Center, 505 Parnassus Ave, Box 0124, San Francisco, Calif 94143 0124, USA
Circulation 107:2697-701. 2003..Nesiritide, recombinant human B-type natriuretic peptide, has been shown to be efficacious in the treatment of decompensated heart failure. The effects of intravenous nesiritide on the human coronary vasculature have not been studied...
- Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trialsJonathan D Sackner-Bernstein
Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
JAMA 293:1900-5. 2005..Nesiritide improves symptoms in patients with acutely decompensated heart failure compared with placebo and appears to be safer than dobutamine. Its short-term safety relative to standard diuretic and vasodilator therapies is less clear...
- [Medical and ventilatory treatment of acute heart failure]Anders Hodt
Nasjonalforeningen for folkehelsen, Det norske hjerte karrådet og Hjerteavdelingen, Aker universitetssykehus, 0514 Oslo
Tidsskr Nor Laegeforen 126:749-52. 2006..In 2005 the European Society of Cardiology published new guidelines on diagnosis and treatment. Also, new therapies have been introduced recently, giving rise to changes in therapeutic concepts...
- Risk of death associated with nesiritide in patients with acutely decompensated heart failureKeith D Aaronson
JAMA 296:1465-6. 2006
- Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgeryA Ahsan Ejaz
Division of Nephrology, Hypertension and Transplantation, University of Florida, Gainesville, FL 32610 0224, USA
J Thorac Cardiovasc Surg 138:959-64. 2009....
- Nesiritide following maze and mitral valve surgeryThomas M Beaver
Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, Florida 36210 0286, USA
J Card Surg 23:431-6. 2008....
- Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA TrialRobert M Mentzer
Division of Cardiothoracic Surgery, Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
J Am Coll Cardiol 49:716-26. 2007..The purpose of this study was to determine the role nesiritide might play in patients with left ventricular dysfunction undergoing coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB)...
- Nesiritide - not verifiedEric J Topol
Case Western Reserve University, Cleveland, USA
N Engl J Med 353:113-6. 2005
- Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency departmentColin A Graham
Southern General Hospital, Glasgow G51 4TF, Scotland, UK
Emerg Med Australas 16:47-54. 2004..The evidence base for 'routine therapy' in the ED is considered. The review also briefly considers emerging pharmacological therapies that may have an impact on future management of cardiogenic pulmonary oedema...
- Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatmentMark A Munger
Department of Pharmacotherapy and Internal Medicine, University of Utah, Salt Lake City, Utah 84112, USA
Pharmacotherapy 27:619-25. 2007....
- [Natriuretic peptides in heart failure]Luis Almenar Bonet
Unidad de Insuficiencia Cardiaca y Trasplante, Servicio de Cardiologia, Hospital Universitario La Fe, Valencia, Spain
Rev Esp Cardiol 6:15-26. 2006....
- Advances in the management of acute and chronic decompensated heart failureSandra L Lowery
CCMI Associates, 1163 New Boston Road, Francestown, NH 03043, USA
Lippincotts Case Manag 9:S1-15; quiz S16-7. 2004..To date the typical treatment of acute decompensation has been based in the hospital and woefully inadequate in promoting any long-term medical stability...
- Decompensated heart failure: is there a role for the outpatient use of nesiritide?Clyde W Yancy
University of Texas Southwestern Medical Center, Department of Internal Medicine Cardiology Division, CS7 102, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA
Congest Heart Fail 10:230-6. 2004..Such an approach, once validated, should be integrated into an evidence-based HF disease management program...
- Safety and efficacy of nesiritide for acute decompensated heart failure: recent literature and upcoming trialsBrian Hiestand
Department of Emergency Medicine, The Ohio State University, 149 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
Curr Cardiol Rep 9:182-6. 2007..We review the recent evidence regarding the efficacy and safety profile of nesiritide, and discuss upcoming trials designed to address concerns regarding safety and the comparative efficacy of nesiritide...
- Nesiritide for acute decompensated heart failure: does the benefit justify the risk?Jonathan Sackner-Bernstein
Clinilabs, Inc, 423 West 55th Street, 4th Floor, New York, NY 10019, USA
Curr Cardiol Rep 9:187-93. 2007..We conclude that with nesiritide, the risks of therapy outweigh the benefits demonstrated to date...
- Alterations in the natriuretic hormone system related to cardiopulmonary bypass in infants with congestive heart failureJ M Costello
Division of Cardiology, Children s Memorial Hospital, The Feinberg School of Medicine at Northwestern University, Chicago, IL 60614 3394, USA
Pediatr Cardiol 25:347-53. 2004....
- Nesiritide therapy for acute heart failureAlice Johnson-Davis
Jeanette Cantrell Rudy School of Nursing, Cumberland University, Lebanon, TN, USA
J Perianesth Nurs 18:386-91. 2003..One of the newest pharmacological therapies for heart failure is nesiritide. The PACU nurse's vital role in the early recognition and early intervention of heart failure may include the administration of this agent...
- Nesiritide in perspective: evolving approaches to the management of acute decompensated heart failureRoger M Mills
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Drugs Today (Barc) 39:767-74. 2003..As with most advances, the process of rolling back the frontiers of knowledge has posed even more questions. However, we must not overlook the progress to date, simply because all of the answers are not yet available...
- Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency departmentCharles L Emerman
Department of Emergency Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Rev Cardiovasc Med 4:S13-20. 2003..This article reviews the initial management of ADHF, the role of early initiation of vasodilator therapy, and the pharmacoeconomics of nesiritide treatment...
- New and emerging drug therapies for the management of acute heart failureH Krum
Department of Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria, Australia
Intern Med J 33:515-20. 2003..This review will examine the key emerging therapies for acute heart failure, in light of available pathophysiological and clinical evidence...
- Nesiritide use for critically ill children awaiting cardiac transplantationR Sehra
Loma Linda University, Del Mar, CA 92014, USA
Pediatr Cardiol 27:47-50. 2006..This study aimed to explore the effects of nesiritide in children awaiting cardiac transplantation...
- Treatment options for acute decompensated heart failureMary Ross Southworth
University of Illinois at Chicago, 840 S Wood Street M C 715, Chicago, IL 60612, USA
Am J Health Syst Pharm 60:S7-15. 2003..It is important to remember that therapy for ADHF should not replace chronic oral heart failure therapy, nor should focus on prevention of ADHF episodes be lost...
- Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failureDoron Aronson
Division of Cardiology, Rambam Medical Center, Haifa, Israel
Am Heart J 148:e16. 2004..We sought to assess the effects of nesiritide compared with dobutamine on time-domain indices of heart rate variability (HRV) in patients with decompensated CHF...
- The natriuretic peptides in cardiovascular medicineVijaya K Munagala
Mayo Clinic, Rochester, Minnesota 55905, USA
Curr Probl Cardiol 29:707-69. 2004..The clinical literature regarding the use of recombinant BNP for the treatment of HF is reviewed, underscoring current gaps in our knowledge regarding the indications for and benefits of this novel agent...
- The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failureW D Strain
National Heart and Lung Institute, Faculty of Medicine, Imperial College London at St Mary s, Norfolk Place, London, UK
Int J Clin Pract 58:1081-7. 2004..When compared to dobutamine, the increased acquisition costs of nesiritide are completely offset by reduced intensity of hospital admissions and reduced readmission rate at 3 weeks...
- Acute decompensated heart failure: best evidence and current practiceR Mehta
Unit of Cardiovascular Diseases, The Ohio State University, Columbus, OH, USA
Minerva Cardioangiol 53:537-47. 2005....
- Optimizing outcomes in the patient with acute decompensated heart failureMandeep R Mehra
Division of Cardiology, Department of Medicine, University of Maryland, Baltimore, MD, USA
Am Heart J 151:571-9. 2006....
- Nesiritide for pulmonary arterial hypertension with decompensated cor pulmonaleMartha S Kingman
Pulmonary Hypertension Group, Pulmonary Hypertension Clinic, Cardiovascular Institute, St Paul University Hospital, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
Prog Cardiovasc Nurs 20:168-72. 2005..A detailed case report is presented followed by the evaluation of a series of 11 cases occurring in eight patients from December 2002 through April 2004...
- Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failureTobias Gerhard
Department of Pharmacy Health Care Administration, University of Florida, P O Box 100496, Gainesville, FL 32610, USA
Pharmacotherapy 26:34-43. 2006..To model the cost-effectiveness of nesiritide compared with dobutamine in patients with decompensated heart failure...
- A review of the natriuretic hormone system's diagnostic and therapeutic potential in critically ill childrenJohn M Costello
Division of Cardiac Intensive Care, Department of Cardiology, Children s Hospital Boston and Harvard Medical School, Boston, MA, USA
Pediatr Crit Care Med 7:308-18. 2006..To review the natriuretic hormone system and discuss its diagnostic, prognostic, and therapeutic potential in critically ill children...
- A prospective evaluation of nesiritide in the treatment of pediatric heart failureJ L Jefferies
Division of Pediatric Cardiology, Texas Children s Hospital, 6621 Fannin, MC 19345 C, Houston, TX 77030, USA
Pediatr Cardiol 27:402-7. 2006..It is associated with decreased thirst and improved urine output and functional status, and it may be efficacious in the treatment of pediatric HF...
- Nesiritide: harmful or harmless?Michael P Dorsch
Department of Pharmacy Services, University of Michigan Hospitals and Health Clinics, Ann Arbor, Michigan 48109 0008, USA
Pharmacotherapy 26:1465-78. 2006..Until these data are available, nesiritide use should be limited...
- Nesiritide in infants and children with congestive heart failureWilliam T Mahle
Sibley Heart Center, Children s Healthcare of Atlanta, and the Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
Pediatr Crit Care Med 6:543-6. 2005..The role of nesiritide in pediatric heart failure has not been examined. In the present study, we reviewed our initial experience with nesiritide in children with primary heart failure or low cardiac output after heart surgery...
- Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failureClaudio Passino
Institute of Clinical Physiology, National Research Council, Pisa, Italy
Int J Cardiol 104:39-45. 2005..We assessed the hypothesis that right ventricular (RV) overload might significantly contribute to plasma elevation of cardiac natriuretic hormones in patients with heart failure...
- Intravenous nesiritide in acute heart failureMark A Knox
Department of Family Medicine, University of Pittsburgh Medical Center Presbyterian Shadyside, Pittsburgh, Pennsylvania 15232, USA
Am J Ther 12:233-7. 2005..Patients who received nesiritide incurred significantly higher charges for medical care, but nesiritide did not affect length of stay, readmission rates, or mortality...
- Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockersWilliam T Abraham
Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210 1252, USA
Congest Heart Fail 11:59-64. 2005..Thus, the clinical and hemodynamic benefits and safety of nesiritide are preserved in decompensated congestive heart failure patients receiving chronic beta blockade...
- Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritideShaun Kurien
Department of Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Am J Cardiol 98:1627-30. 2006....
- Short and long-term mortality with nesiritideRohit R Arora
The Department of Medicine, The Chicago Medical School, Chicago, IL 60064, USA
Am Heart J 152:1084-90. 2006..We performed a meta-analysis of 7 available randomized controlled trials to evaluate the short- and long-term risk of death with nesiritide use for acute decompensated heart failure...
- Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failureMitchell T Saltzberg
Midwest Heart Specialists HeartFailure Program, Midwest Heart Foundation Echocardiographic Core Laboratory, Downers Grove, Illinois, USA
Rev Cardiovasc Med 5:S17-27. 2004..Nesiritide, a human recombinant B-type natriuretic peptide, is a safe, effective vasodilator that can be easily used early in the emergency department to improve outcomes in ADHF...
- Current and novel pharmacological approaches to renal insufficiency in heart failureV Hindnavis
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
Minerva Cardioangiol 54:753-62. 2006..These include natriuretic peptides and other vasodilators, adenosine receptor antagonists, and vasopressin receptor antagonists all currently undergoing late-stage clinical trials...
- Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trialBradley A Bart
Minnesota Heart Failure Consortium, Minneapolis, Minnesota, USA
J Am Coll Cardiol 46:2043-6. 2005..The purpose of this research was to assess the safety and efficacy of ultrafiltration (UF) in patients admitted with decompensated congestive heart failure (CHF)...
- Sustained use of nesiritide to aid in bridging to heart transplantJames A Hill
Heart Failure Transplantation Program, Division of Cardiology, University of Florida, Gainesville, Florida, USA
Clin Cardiol 26:211-4. 2003..This suggests that new strategies for pretransplant management may be needed...
- Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failureDalane W Kitzman
Section of Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1045
JAMA 288:2144-50. 2002..However, the pathophysiology of this disorder, presumptively termed diastolic heart failure (DHF), is not well characterized and it is unknown whether it represents true heart failure...
- Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT studyAndrew J Burger
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 02215, USA
Am Heart J 144:1102-8. 2002..In this randomized, multicenter trial, we compared the safety and clinical effectiveness of the cardiac hormone nesiritide (human B-type natriuretic peptide) with dobutamine in hospitalized patients with decompensated CHF...
- New advances and novel treatments in heart failureAndrew Lee Smith
Center for Heart Failure Therapy, Emory University Hospital, Atlanta, GA, USA
Crit Care Nurse . 2003....
- Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritideJohn A Noviasky
Department of Pharmacy, St Elizabeth Medical Center, Utica, New York 13501, USA
Pharmacotherapy 27:626-32. 2007..After review of this article, the reader should be able to answer the question--if nesiritide had never been approved for use in patients with ADHF, would we have missed it?--with a negative reply...
- Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failureGregory de Lissovoy
MEDTAP International, Inc, Bethesda, Maryland 20814, USA
Am J Cardiol 92:631-3. 2003..Results indicate that the acquisition cost of nesiritide is fully offset by decreased hospital costs...
- Nesiritide (Natrecor): a new treatment for acutely decompensated congestive heart failureKatberine Colbert
The Southside Regional Medical Center, Petersburg, VA, USA
Crit Care Nurs Q 26:40-4. 2003..The neurohormonal effects of endogenous BNP are reproduced by nesiritide. Indications, dosing, administration, and review of clinical trials are presented in this article...
- "BNP" for heart failure: role of nesiritide in cardiovascular therapeuticsRoger M Mills
Kaufman Center for Heart Failure, Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Congest Heart Fail 8:270-3. 2002..In this review, the authors summarize the currently available data regarding the use of nesiritide, and offer recommendations for its use based on our experience with the compound in clinical trials...
- Using BNP to diagnose, manage, and treat heart failureRobert E Hobbs
Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, The Cleveland Clinic, Cleveland Clinic Foundation, OH 44195, USA
Cleve Clin J Med 70:333-6. 2003..A synthetic formulation of BNP (nesiritide) is used to treat decompensated heart failure, resulting in improved hemodynamics and symptoms...
- Rapid optimization: strategies for optimal care of decompensated congestive heart-failure patients in the emergency departmentW Frank Peacock
Department of Emergency Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Rev Cardiovasc Med 3:S41-8. 2002....
- Pharmacologic therapies for acutely decompensated heart failureGregg C Fonarow
Division of Cardiology, UCLA School of Medicine, Los Angeles, California, USA
Rev Cardiovasc Med 3:S18-27. 2002....
- Administration of brain natriuretic peptide improves cardiac function following operations using extracorporeal circulation in an animal modelDorothee H L Bail
Department of Thoracic, Cardiac and Vascular Surgery, University of Tubingen, Hoppe Seyler Str 3, D 72076 Tubingen, Germany
Clin Sci (Lond) 112:315-24. 2007..In conclusion, administration of BNP is highly effective in treating post-ischaemic heart failure following ECC. Haemodynamics are greatly improved, and there is almost no need for pharmacological support...
- Atrial natriuretic factor: neuromodulator of the central nervous system regulation of blood pressureE R Levin
Department of Medicine, Long Beach Veterans Hospital, CA 90822
Am J Hypertens 2:594-8. 1989..Experiments from other laboratories indicate that central ANF may modulate the pressor effects of centrally acting angiotensin II.(ABSTRACT TRUNCATED AT 250 WORDS)..
- Aldosterone biosynthesis, regulation, and classical mechanism of actionGordon H Williams
Division of Endocrinology, Diabetes and Hypertension, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Heart Fail Rev 10:7-13. 2005..Aldosterone's biosynthesis appears to be regulated in these tissues similar to what occurs in the adrenal cortex. The role of this extra adrenal aldosterone production in health and disease is as of yet undetermined...
- mPGES-1 deletion impairs aldosterone escape and enhances sodium appetiteZhanjun Jia
Department of Internal Medicine, University of Utah and Veterans Affairs Medical Center, Salt Lake City, Utah 84132, USA
Am J Physiol Renal Physiol 299:F155-66. 2010..Together, these results suggest an important role of mPGES-1 in antagonizing the sodium-retaining action of Aldo at the levels of both the central nervous system and the kidney...
- Membrane guanylate cyclase signal transduction systemR K Sharma
UMDNJ, SOM, Department of Cell Biology, New Jersey 08084, USA
Indian J Biochem Biophys 34:40-9. 1997..This review will briefly discuss the fascinating, albeit turbulent, history of this signal transduction field, which will be followed by its current status and finally the direction it is heading...
- Cerebral salt wasting syndrome: reviewM Cerda-Esteve
Endocrinology Department, Hospital Universitari del Mar, Universitat Autonoma de Barcelona, Barcelona, Spain
Eur J Intern Med 19:249-54. 2008..The essential point is the volemic state. It is necessary to rule out other intermediate causes. Treatment requires volume replacement and maintenance of a positive salt balance. Mineral corticoids may be useful in complicated cases...
- Natriuresis of fasting: the possible role of leptin-neuropeptide Y systemE Sulyok
County Children s Hospital, H 7624 Pecs, Hungary
Med Hypotheses 56:629-33. 2001..4. This sequence of events implies that NPY contributes to natriuresis that occurs in response to fasting...
- Antihypertensive action of beta-adrenoceptor blocking drugs. The role of intrarenal mechanismsH A Struyker-Boudier
Department of Pharmacology, University of Limburg, Maastricht, The Netherlands
Am J Hypertens 2:237S-240S. 1989..The possible mechanisms of renal vasodilatation of tertatolol are reviewed. It is concluded that the shift of the renal pressure-diuresis curve is an essential feature in the mode of long-term antihypertensive action of beta-blockers...
- Gene expression profile during acute rejection in rat-to-mouse concordant cardiac xenograft by means of DNA microarrayAkio Saiura
Department of Molecular Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan
Transpl Int 15:535-40. 2002..In addition to known genes, many expressed sequence tags were induced in the xenografts. We identified a group of genes, including Mac-1 induced specifically in xenografts, as well as many new genes upregulated in xenografts...
- AliskirenMorris J Brown
University of Cambridge, Cambridge, UK
Circulation 118:773-84. 2008..understanding of the renin system will maximize its value, for instance, by encouraging greater use of natriuretic agents in patients with resistant hypertension to render their hypertension renin dependent...
- Cerebral salt wasting syndromeM R Harrigan
Department of Surgery, Section of Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA
Crit Care Clin 17:125-38. 2001..Future investigation is needed to better define the incidence of CSW in patients with intracranial disease, identify other disorders that can lead to CSW, and elucidate the mechanisms underlying this syndrome...
- Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to a nitric oxide donor in the pregnant ratJennifer M Sasser
Dept of Physiology and Functional Genomics, Univ of Florida, PO Box 100274, Gainesville, FL 32610, USA
Am J Physiol Renal Physiol 299:F810-4. 2010..Therefore, increased intrarenal PDE5 mediates the blunted natriuretic response to NO, and loss of responsiveness to the cGMP-dependent, natriuretic agents may contribute to volume expansion during pregnancy.
- Natriuretic peptide response to dynamic exercise in patients with atrial fibrillationMads D M Engelmann
Department of Cardiology, Herlev University Hospital, Herlev, Denmark
Int J Cardiol 105:31-9. 2005..The aim of this study was to investigate plasma ANP and BNP response to exercise in patients with permanent AF and to assess if the response was different from the response in healthy age- and sex-matched control subjects...
- Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HFRobert J Mentz
Duke University Medical Center, Durham, NC, USA
Eur J Heart Fail 15:456-64. 2013..To examine the characteristics associated with early dyspnoea relief during acute heart failure (HF) hospitalization, and its association with 30-day outcomes...
- Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-oneHaifeng Tang
Department of Medicinal Chemistry, Rahway, NJ 07065, United States Department of Ions Channels, Cardiovascular Disease, Rahway, NJ 07065, United States Department of Drug Metabolism and Pharmacology, Rahway, NJ 07065, United States Department of Merck Research Laboratories, Rahway, NJ 07065, United States Electronic address
Bioorg Med Chem Lett 23:5829-32. 2013..inhibitors were characterized for the first in vivo proof-of-concept biology studies, and results from an acute rat diuresis model confirmed the hypothesis that ROMK inhibitors represent new mechanism diuretic and natriuretic agents.
- Hemodynamic optimization in high-risk mitral valve repairs as a key component in surgical readinessRajan Kanth
Department of Internal Medicine, Marshfield Clinic, 1000 N Oak Ave, Marshfield, WI 54449, USA
WMJ 112:69-73. 2013..This case report illustrates the importance of a systemic approach with high-risk surgery, and the use of strategies that optimize key patient factors, including hemodynamics, prior to all elective and urgent procedures...
- Brain natriuretic peptide in heart failure and beyondMohammad M Mowla
Division of Cardiac Sciences, Department of Medicine, King Abdul Aziz National Guard Hospital, PO Box 2477, Al Ahsa 31982, Kingdom Saudi Arabia
Saudi Med J 27:1457-61. 2006..This paper reviews the available literature concerning the BNP and N-terminal pro brain-type natriuretic peptide to assess their role in current medical practice...
- Nesiritide in acute decompensated heart failure: a pooled analysis of randomized controlled trialsWilliam T Abraham
Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA
Clin Cardiol 33:484-9. 2010..This study used relevant data from all RCTs of nesiritide in ADHF completed as of June 2006 to independently estimate the effect of nesiritide on 30- and 180-day mortality...
- Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trialsGianluigi Savarese
Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy
PLoS ONE 8:e58287. 2013..The purpose of this study was to evaluate whether natriuretic peptide-guided therapy, compared to clinically-guided therapy, improves mortality and hospitalization rate in patients with chronic HF...
- The use of nesiritide in the management of acute decompensated heart failure. 2002Steven R Kayser
Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94143 0622, USA
Prog Cardiovasc Nurs 22:89-95. 2007
- [BNP or NT-proBNP: "that is the question"]C Lebrun
Service de Biochimie, Centre Hospitalier de Chambery
Ann Biol Clin (Paris) 65:533-8. 2007..It is clear that all Diagnostics Manufacturers should now propose different cut-off for natriuretic peptides tests according to the degree of patients' renal impairment...
- Acute heart failure: perspectives from a randomized trial and a simultaneous registryJustin A Ezekowitz
Mazankowski Alberta Heart Institute and the University of Alberta, Edmonton, AB, Canada
Circ Heart Fail 5:735-41. 2012....
- C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockadeBrian Casserly
Department of Medicine, Alpert Medical School of Brown University, Providence, RI 02912, USA
Life Sci 89:460-6. 2011..The purpose of this study was to determine if CNP is capable of preventing the development of pulmonary hypertension (PH)...
- [Tako-Tsubo syndrome during normal human immunoglobolin perfusion]P Gautier
Unité de réanimation polyvalente et soins intensifs cardiaques, Médecine Interne et Cardiologie, centre hospitalier Jacques Lacarin, Vichy, France
Ann Cardiol Angeiol (Paris) 60:290-5. 2011..Also, MRI ruled out inflammatory and ischemic cardiac diseases. The most likely diagnosis for us was Tako-Tsubo syndrome in relation with injection of Human Normal Immunoglobulin (Tegeline(®)) according to the Mayo clinic criteria...
- Nesiritide: trials and tribulationsRohit R Arora
Department of Medicine, The Chicago Medical School, Chicago, Illinois, USA
J Cardiovasc Pharmacol Ther 11:165-9. 2006....
- Perioperative nesiritide versus milrinone in high-risk coronary artery bypass graft patientsMarcia L Brackbill
Department of Pharmacy Practice, Bernard J Dunn School of Pharmacy, Shenandoah University, Winchester, VA 22601, USA
Ann Pharmacother 41:427-32. 2007..Nesiritide may attenuate the body's neurohormonal response to myocardial stretch after CABG and provide clinical benefit in the immediate postoperative period...
- C-type natriuretic peptide hyperpolarizes and relaxes human penile resistance arteriesAttila Kun
Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary
J Sex Med 5:1114-25. 2008..Recently, it has been shown that C-type natriuretic peptide (CNP) shows the characteristics of EDHF in systemic small arteries...
- Novel agents in cystic fibrosisShane Storey
Nat Rev Drug Discov 7:555-6. 2008
- Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failureClyde W Yancy
Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas 75246, USA
Drug Saf 30:765-81. 2007..When used for approved indications and according to recommended dosage and administration regimens, nesiritide represents a reasonable treatment adjunct for ADHF...
- Hemodynamic effects and safety of nesiritide in neonates with heart failureJanet M Simsic
Sibley Heart Center Cardiology Children s Healthcare of Atlanta, 2835 Brandywine Road, Atlanta, GA 30341, USA
J Intensive Care Med 23:389-95. 2008..Evaluate effects and safety of nesiritide (Natrecor, Scios Inc.) human B-type natriuretic peptide, in neonates with heart failure...
- Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)Justin A Ezekowitz
University of Alberta, Edmonton, Canada
Am Heart J 157:219-28. 2009..This review provides key practical information regarding the current standard of care for patients with ADHF including the goals of therapy, management of acute and chronic medications, and discharge/transition of care planning...
- Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMACMandeep R Mehra
University of Maryland School of Medicine, Baltimore, MD 21201 1595, USA
Am Heart J 153:932-40. 2007....
- Molecular and physiological effects of nesiritideS Reichert
University of British Columbia, Vancouver, British Columbia
Can J Cardiol 24:15B-8B. 2008....
- Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)Adrian F Hernandez
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 157:271-7. 2009..However, the effect of nesiritide on dyspnea at 6 or 24 hours is unknown, and no clinical outcome trials have been done to provide a reliable estimate of the effect of nesiritide on morbidity and mortality...
- Intracellular signaling pathways involved in inhibition of PAI-1 expression by CNP in endothelial cellsH Jerczynska
Department of Molecular and Medical Biophysics, Medical University in Lodz, Lodz, Poland
Regul Pept 155:150-5. 2009..These data suggest that CNP might function as the natural defense of vascular wall against cytokine induced PAI-1 release through its ability to inactivate PI3K/AKT and MEK/ERK pathways...
- Natriuretic peptides as regulatory mediators of secretory activity in the digestive systemMaria Eugenia Sabbatini
Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109 5622, United States
Regul Pept 154:5-15. 2009..Overall, these findings indicate that ANP and CNP are members of the large group of regulatory peptides affecting digestive secretions...
- Nesiritide enhances myocardial protection during the revascularization of acutely ischemic myocardiumHarold L Lazar
Department of Cardiothoracic Surgery, Boston Medical Center, Boston, MA 02118, USA
J Card Surg 24:600-5. 2009..This study was, therefore, undertaken to determine whether nesiritide alone could enhance myocardial protection when given intraoperatively in a porcine model simulating urgent coronary artery bypass graft surgery...
- [The role of vitamin D in the development of cardiac failure]Boglárka Szabó
Semmelweis Egyetem, Általános Orvostudományi Kar, Kardiológiai Központ, Budapest
Orv Hetil 150:1397-402. 2009..In spite of the robust preclinical data only few clinical observations prove the positive effect of vitamin D on congestive heart failure...
- Atrial natriuretic peptide and renal dopaminergic system: a positive friendly relationship?Marcelo Roberto Choi
Department of Pathophysiology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, CONICET, INFIBIOC, 1113 Buenos Aires, Argentina
Biomed Res Int 2014:710781. 2014....
- Brain natriuretic peptide improves long-term functional recovery after acute CNS injury in miceMichael L James
Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina 27710, USA
J Neurotrauma 27:217-28. 2010..hBNP improves neurological function in murine models of TBI and ICH, and was associated with enhanced CBF and downregulation of neuroinflammatory responses. hBNP may represent a novel therapeutic strategy after acute CNS injury...
- Efficacy and safety of nesiritide in patients with acute decompensated heart failureTracy A Dewald
Division of Clinical Pharmacology, Duke University Medical Center, Box 3943 Medical Center, Durham, NC 27710, USA
Expert Rev Cardiovasc Ther 8:159-69. 2010..However, the pathophysiology of acute decompensated heart failure is complex and the impact of nesiritide on important clinical end points, beyond symptomatic and hemodynamic improvement, is unknown...
- Are extracellular osmolality and sodium concentration determined by Donnan effects of intracellular protein charges and of pumped sodium?Sven Kurbel
Department of Physiology, Osijek Medical Faculty, J Huttlera 4, 31000 Osijek, Croatia
J Theor Biol 252:769-72. 2008..Individual cells can reduce eventual residual osmotic forces on their membrane through altering cell volume by chloride shift, and by modulating the Na+K+-ATPase function...
- [The best of clinical pharmacology in 2002]M Andrejak
Service de Pharmacologie Clinique, CHU, Hopital Sud, 80054 Amiens
Arch Mal Coeur Vaiss 96:41-50. 2003..Finally, 2002 was marked by the publication of the WHI study which intensified suspicions regarding hormonal substitution treatment, confirming the advantage of not only secondary but perhaps primary cardiovascular prevention...
- Turn back the tide of cardiogenic pulmonary edemaMarcia Bixby
Beth Israel Deaconess Medical Center, Boston, MA, USA
Nursing 35:56-60; quiz 60-1. 2005
- Evaluating ventricular function with B-type natriuretic peptide in obstetric patientsJohn J Folk
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, State University of New York Upstate Medical University, Syracuse, New York 13210, USA
J Reprod Med 50:147-54. 2005..To determine if a rapid serum assay for B-type natriuretic peptide (BNP) provides information regarding ventricular function in obstetric patients with acute dyspnea...
- Mouse natriuretic peptide receptor 3 gene maps to proximal chromosome 15O V Savinova
Jackson Laboratory, Bar Harbor, Maine 04609, USA
Mamm Genome 8:788. 1997
- Blood pressure and endocrine responses of healthy subjects in cold pressor test after acutely increased dietary sodium intakeO Arjamaa
Center of Arctic Medicine, University of Oulu, Oulu, Finland
J Physiol Anthropol Appl Human Sci 20:207-12. 2001..To conclude, acutely increased sodium intake does not change blood pressure or hormonal responses in a cold pressor test in young healthy subjects...
- Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinineDavid J Wang
Department of Medicine, University of Maryland School of Medicine, and Baltimore Veterans Administration Medical Center, USA
Circulation 110:1620-5. 2004..However, studies of brain natriuretic peptide in patients with heart failure have come to conflicting conclusions about effects on glomerular filtration rate (GFR), effective renal plasma flow, natriuresis, and diuresis...
- [Cardiovascular abnormalities as a cause of hypertension]H Takano
Department of Medicine III, Chiba University School of Medicine
Nippon Rinsho 59:867-71. 2001..On the other hand, vasodilator neurohumoral factors such as natriuretic peptides and adrenomedulin inhibit VSMCs proliferation. Both neurohumoral factors mutually interact and develop hypertension...
- Physiological Regulation of MLCK in Intact ArteriesWithrow Gil Wier; Fiscal Year: 2013..This research will utilize a mouse model of salt-induced hypertension to provide specific new information on the role of MLCK in high blood pressure. ..
- SODIUM AND CALCIUM METABOLISM IN PREHYPERTENSIVE STATEVito Campese; Fiscal Year: 1990....
- APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTSWilliam Wechter; Fiscal Year: 2001....
- REPRODUCTIVE ENDOCRINOLOGY OF CNS ATRIAL PEPTIDESWILLIS SAMSON; Fiscal Year: 1990....
- ACTION - A CHF Trial Investigating Outcomes of ExerciseCHRISTOPHER O CONNOR; Fiscal Year: 2008..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
- NO AND OXIDATIVE STRESS IN HUMAN MYOCARDIAL FAILUREMichael Givertz; Fiscal Year: 2003..abstract_text> ..
- SCHOLARS IN CLINICAL SCIENCE PROGRAMGordon Williams; Fiscal Year: 2004..abstract_text> ..
- Inflammation & Prognosis in Decompensated Heart FailureGARY FELKER; Fiscal Year: 2008..Felker's development into an established independent clinical investigator with expertise in both complex clinical research methodology and the role of inflammation in the pathophysiology of heart failure. ..
- Non-Modulation Phenotype and Vascular Dysfunction in Diabetes MellitusGordon H Williams; Fiscal Year: 2010....
- Na,K-ATPase alpha4 isoform in male germ cell physiologyV GUSTAVO BLANCO; Fiscal Year: 2010..abstract_text> ..
- ISOLATED DIASTOLIC DYSFUNCTIONMARGARET REDFIELD; Fiscal Year: 2008....
- Aldosterone, Histone Demethylase and Cardiovascular DiseaseGordon H Williams; Fiscal Year: 2010..This project is designed to assess one of those mechanisms thereby providing entrie to developing more directed therapy to treat cardiovascular diseases. ..
- CHF TRIAL INVESTIGATING OUTCOMES OF EXERCISE TRAININGDalane Kitzman; Fiscal Year: 2007..abstract_text> ..
- Mechanisms of Aldosterone Induced Cardiovascular DamageGordon Williams; Fiscal Year: 2006..Our results should better define the rationale for the use of mineralocorticoid receptor antagonists to prevent damage to the heart and other tissues when ALDO levels are inappropriate relative to Na intake. ..
- Decision Making in End-Stage Heart FailurePaul Hauptman; Fiscal Year: 2006..unreadable] [unreadable] [unreadable]..
- VASCULAR DISEASE IN HBP--ANGII, PAI1, INSULIN AND GENESGordon Williams; Fiscal Year: 2001..With this information, specific preventive and therapeutic measures to retard the development of these complications could be proposed and tested in a clinical trial's format. ..
- PREDICTING AND IMPROVING OUTCOMES IN ACUTE RENAL FAILURERavindra Mehta; Fiscal Year: 2001..It is anticipated (by the applicants) that information gained from this study, being largely observational, will be used to rationally design intervention strategies in future years. ..
- ACTION-A CHF TRIAL INVESTIGATING OUTCOMES OF EXERCISEWilliam Abraham; Fiscal Year: 2005..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
- Septate junctional proteins: Proteomic identification and role in diuresisKLAUS BEYENBACH; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- EXERCISE INTOLERANCE IN ELDERLY DIASTOLIC HEART FAILUREDalane Kitzman; Fiscal Year: 2004..abstract_text> ..
- Cyclic GMP And Ventricular Function In Heart FailureMARGARET REDFIELD; Fiscal Year: 2003..abstract_text> ..